BioWorld. Link to homepage.
BioWorld
BioWorld MedTech
BioWorld Asia
BioWorld Science
Data Snapshots
BioWorld
BioWorld MedTech
Infographics: Dynamic digital data analysis
Special reports
Aging
Alzheimer's disease
Artificial intelligence
Biosimilars
China CAR T
Coronavirus
Infographics: Dynamic digital data analysis
Israel
IVDs on the rise
Radiopharmaceuticals
Rise of obesity
Top Biopharma Trends of 2023
Top Med-tech Trends of 2023
Top Preclinical Trends of 2023
Premium reports
BioWorld Financings Reports
Disease Incidence & Prevalence Summaries
BioWorld. Link to homepage.
sign in
Sign Out
My Account
Subscribe
BioWorld - Friday, April 26, 2024
Home
»
Newsletters
» BioWorld
BioWorld
Jan. 4, 2008
View Archived Issues
Rights to Schizophrenia Drug Worth up to $702M for Addex
Swiss biotech Addex Pharmaceuticals has granted rights to Merck & Co. Inc. to develop ADX63365, an investigational treatment for schizophrenia, in a deal potentially worth $702 million. (BioWorld Today)
Read More
Crucell Signs Sanofi Pasteur in $113M Rabies Antibodies Deal
Read More
ImmunoGen Entering TAP Cancer Deal with Centocor
Read More
Gelesis Closes $16M Series A to Fund its Obesity Program
Read More
QuatRx Meets all Endpoints in Ophena Phase III Trial
Read More
Other News To Note
Read More
Clinic Roundup
Read More